Analyst Research
| Report Title | Price |
|---|---|
|
Provider: S&P Capital IQ Quantitative Report
|
$69.00
|
|
Provider: Wright Reports
|
$449.00
|
|
Provider: Reuters Investment Profile
|
$20.00
|
|
Provider: Thomson Reuters Stock Report
|
$25.00
|
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
Accuray Incorporated Announces Proposed Offering Of $75 Million Convertible Senior Notes
Accuray Incorporated announced its intention to commence an offering, subject to market and other conditions, of $75 million aggregate principal amount of convertible senior notes due 2016, to be offered and sold to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended. Accuray intends to grant the initial purchaser of the notes an option to purchase up to an additional $11.25 million aggregate principal amount of notes. The notes are expected to be convertible under certain conditions into common stock of Accuray, cash or a combination thereof, at Accuray's election. The notes are expected to mature on August 1, 2016, unless earlier repurchased, redeemed or converted. The notes are expected to be redeemable at a redemption price of 100% of their principal amount plus accrued and unpaid interest, at Accuray's option on or after August 1, 2014 if the closing sale price of its common stock exceeds 130% of the applicable conversion price of the notes for specified periods. The interest rate, conversion rate and other terms of the notes are to be determined by negotiations between Accuray and the initial purchaser of the notes. Accuray intends to use the proceeds from the sale of the notes for general corporate purposes, including investing strategically in expanding its business and new product initiatives.
Latest Developments for Accuray Inc
- Accuray Inc Lowers FY 2013 Revenue Guidance-Conference Call
- Accuray Inc Reaffirms FY 2013 Revenue Guidance; Issues Q3 2013 Revenue Guidance In Line With Analysts' Estimates-Conference Call
- Accuray Inc Issues Q2 2013 Guidance; Revenue Guidance In Line With Analysts' Estimates; Lowers FY 2013 Guidance-Conference Call
- 90 Presentations At Radiation Oncology Meeting Demonstrate Breadth And Depth Of Clinical Evidence For Accuray Inc
Latest Key Developments in Advanced
- Covidien PLC Approves Separation Of Pharmaceuticals Business And Declares Dividend Of Mallinckrodt Ordinary Shares
- Nephros Inc Announces Completion Of Rights Offering
- Volcano Corp Announces Preliminary Results From ADVISE II Study
- Nordion Inc Enters Into Agreement To Divest Targeted Therapies Business To BTG Plc
- Share this
- Link this
- Digg this


Follow Reuters